1. Home
  2. GBIO vs WVVI Comparison

GBIO vs WVVI Comparison

Compare GBIO & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • WVVI
  • Stock Information
  • Founded
  • GBIO 2016
  • WVVI 1983
  • Country
  • GBIO United States
  • WVVI United States
  • Employees
  • GBIO N/A
  • WVVI N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • WVVI Beverages (Production/Distribution)
  • Sector
  • GBIO Health Care
  • WVVI Consumer Staples
  • Exchange
  • GBIO Nasdaq
  • WVVI Nasdaq
  • Market Cap
  • GBIO 29.5M
  • WVVI 28.2M
  • IPO Year
  • GBIO 2020
  • WVVI N/A
  • Fundamental
  • Price
  • GBIO $4.37
  • WVVI $4.85
  • Analyst Decision
  • GBIO Strong Buy
  • WVVI
  • Analyst Count
  • GBIO 4
  • WVVI 0
  • Target Price
  • GBIO $73.33
  • WVVI N/A
  • AVG Volume (30 Days)
  • GBIO 210.2K
  • WVVI 9.8K
  • Earning Date
  • GBIO 08-06-2025
  • WVVI 08-12-2025
  • Dividend Yield
  • GBIO N/A
  • WVVI N/A
  • EPS Growth
  • GBIO N/A
  • WVVI N/A
  • EPS
  • GBIO N/A
  • WVVI N/A
  • Revenue
  • GBIO $24,556,000.00
  • WVVI $38,520,945.00
  • Revenue This Year
  • GBIO N/A
  • WVVI N/A
  • Revenue Next Year
  • GBIO N/A
  • WVVI N/A
  • P/E Ratio
  • GBIO N/A
  • WVVI N/A
  • Revenue Growth
  • GBIO 146.47
  • WVVI N/A
  • 52 Week Low
  • GBIO $3.00
  • WVVI $3.17
  • 52 Week High
  • GBIO $35.80
  • WVVI $7.18
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 53.21
  • WVVI 38.42
  • Support Level
  • GBIO $4.28
  • WVVI $4.78
  • Resistance Level
  • GBIO $5.10
  • WVVI $4.95
  • Average True Range (ATR)
  • GBIO 0.62
  • WVVI 0.19
  • MACD
  • GBIO 0.01
  • WVVI -0.01
  • Stochastic Oscillator
  • GBIO 30.16
  • WVVI 22.34

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About WVVI Willamette Valley Vineyards Inc.

Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.

Share on Social Networks: